Two-year follow-up of KEYNOTE-365 cohort D: Pembrolizumab (pembro) plus abiraterone acetate (abi) and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)
ANNALS OF ONCOLOGY(2022)
Abstract
Initial analysis of Cohort D of the phase 1b/2 KEYNOTE-365 (NCT02861573) study showed pembro + abi and prednisone had antitumor activity and acceptable safety in patients (pts) with chemotherapy-naive mCRPC. Two-year follow-up is presented.
MoreTranslated text
Key words
pembrolizumab,prostate cancer,prednisone,two-year,chemotherapy-naive,castration-resistant
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined